Joe Bennett MD

Congratulations to Jesus Gonzalez Lugo, MD, recipient of the Winn Career Development Award, a national program that supports clinicians leading community‑focused clinical research. Learn more: bit.ly/4sSukOq

Bruton Tyrosine Kinase Inhibition in Combination With Bispecific Antibodies for Richter's Syndrome: A Report of Two Cases and Mini Review. cureus.com/articles/45042… #Lymsm #CLL #Richters

We are thrilled to see @KUcancercenter University of Kansas Cancer Center recognized among the Top 50 Cancer Centers worldwide on the LARVOL scale—a tremendous achievement made possible with the support of @JOEBENNETTMD. @Larvol @USMIRCNEWS @US_HMC @oncodaily @MedwatchKate

@BuffettCancer @lymphomaphilia Congrats!

Join us in celebrating @lymphomaphilia -- the first recipient of the endowed James O. Armitage, MD, Chair in Hematological Malignancies! A fitting honor for an internationally recognized lymphoma expert. Read more: unmc.edu/newsroom/2025/…

Hematology Fellows Remember this flow pattern! APL: Promyelocytes one step more differentiated from myeloblasts and lose CD34 expression. Blasts typically CD34+, but APL CD34-/ CD13+, CD33+, CD117+, MPO+, CD34-, HLADR-

Dr. Marc Hoffmann @KUcancercenter presented Golcadomide + Rituximab in R/R NHL. Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase 1/2 study extended follow-up Results Median 4L prior therapy, many CAR-T exposed / Bispecific exposed, 0.4mg Golca ORR 58% in all patients, ctDNA deep reductions even in high risk TP53mut disease. Promising data! #ASH25 #lymsm

@DrJasonWestin presented R-CHOP + Golcadomide. High rates of MRD negativity by ctDNA, safety data is encouraging. Phase 3 GOLSEEK-1 is pending. #lymsm

Final analysis of ROSEWOOD 3L setting Zanubrutinib + Obinutuzumab (Z+O). ORR 70%, CR 42%, TTNT 51mo. mOS not reached. TRAE 9.8% stopped from AEs. Obinutuzumab definitely active with prior Rituximab in cFL. Patient selection is key, several good options cFL. #ASH2025 #lymsm

@Abdallah81MD @KUcancercenter @AlmaHabibMD @USMIRCNEWS @OncoAlert Welcome @AlmaHabibMD !!! 🎉🎈🎊

I’m thrilled to officially welcome our newest member at HMCT @KUcancercenter — the amazing @AlmaHabibMD 🎉 She’s joining the BMT team and we couldn’t be more excited to have her on board! 🌟💉🩺 #ICE_T #mmsm #MedEd #myeloma #MedTwitter #USMIRC @USMIRCNEWS @OncoAlert #سرطان_الدم #المايلوما @oncodaily

⏳2 days left for the 1st National ICE-T meeting #mmsm #USMIRC @OncoAlert @oncodaily @NausheenAhmedMD @HemSandoval @mshahzadmd @mumairmushtaq @kczmj @anup_kasi @AtrashShebli @medicalwatchBC @Larvol eeds.com/portal_live_ev…

Zanubrutinib demonstrated reduced risk of progression/death compared to ibrutinib, acalabrutinib, and bendamustine or idelalisib+rituximab. ow.ly/HtOG50WfGUG #lymphoidneoplasia

@ShetalLife77 I’ll be full time, malignant hematology, specializing in lymphoma at U Kansas 🤓🤓🤓

@JOEBENNETTMD So what’s this exciting next phase? Don’t leave us hanging like those unfinished charts.

Goodbye fellow cubicle, we anxiously await the attending office. Many hours spent here: charting, editing papers, studying, spinning the proverbial hamster wheel. Ready for the next phase of my career!

We’re in Briarcliff! Now patients have 3 locations to choose from in the Northland. Ranked in the top 1% nationwide, #KUCancerCenter offers unrivaled expertise and experience in diagnosing and treating all forms of cancer. Learn more: bit.ly/3ZGWiQI

Structured Exercise after Adjuvant Chemo for Colon Cancer ⁦@KUHemOncFellow⁩ with Dr. Sunny Cai and Dr. ⁦@lihaoran⁩ . Good for all cancer patients to exercise post-chemo, but especially CRC! 🏃🏊 #MedTwitter #ColonCancer #ExerciseIsmedicine nejm.org/doi/full/10.10…

@KUHemOncFellow journal club today with Drs. @lihaoran and Sunny Cai. 🏃‍♂️💪 Colon cancer survivors Structured aerobic + resistance training after chemo cut recurrence risk: ➡️ DFS HR = 0.72 , p=0.02 28% risk reduction! nejm.org/doi/full/10.10… #OncoFit #ColorectalCancer #NEJM #MedTwitter #ExerciseIsMedicine

Prophy dex with glofitamab (4 mg after 1st glofi & bid for 3 days after C1D8, C1D15, C2D1) with reduction in CRS from 63% in trial to 32%, all G1-2. Moving towards outpatient glofi. #18ICML #lymsm

Excited to dive into this one for some casual reading. It’s a small book so should be quick read. I’ll post my thoughts once finished :) #MedTwitter #Hematology

This is an interesting concept and T cell exhaustion is an important focus for treatment failures. Multi-virus specific T cells to enhance the activity of bispecific antibodies in lymphoma by ⁦@AkivaDiamond⁩ #Lymsm #lymphoma #ASCO25 ascopubs.org/doi/10.1200/JC…